What Is Tesamorelin? A GHRH Analog Research Guide

By the NUPEPS Research Team · September 2026

At a Glance

• Compound: Tesamorelin
• Type: Synthetic GHRH analog — 44 amino acids
• Modification: N-terminal trans-3-hexenoyl group
• Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular weight: ~5,136 daltons
• CAS number: 218949-48-5
• Development code: TH9507
• Clinical trade name: Egrifta
• FDA status: Approved 2010 (prescription-only) for excess abdominal fat in HIV-associated lipodystrophy
• Research supply: Tesamorelin 10 mg lyophilized powder, for laboratory research use only

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone–releasing hormone (GHRH), distinguished by an N-terminal trans-3-hexenoyl modification that differentiates it from the native hormone. Developed under the code name TH9507, it is the most extensively studied GHRH analog in the published literature, with multiple randomized controlled trials investigating its effects on GH-axis signaling, adipose tissue, liver fat, and cognition.

Tesamorelin received FDA approval in 2010 as a prescription medicine (Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Research-grade tesamorelin supplied by NUPEPS PEPTIDES is strictly for laboratory and in vitro research use — never for human or veterinary use.

Scope note: this guide summarizes published scientific literature for research reference. Tesamorelin is a prescription medicine in clinical settings; the research material discussed here is sold for in vitro and analytical research only — never for human or veterinary use.

What Is Tesamorelin, and How Was It Developed?

Tesamorelin was developed by Theratechnologies (as TH9507) as a stabilized analog of endogenous human GHRH. The design rationale, described in the peptide literature, was to preserve the full 44-amino-acid GHRH sequence — the form that binds the GHRH receptor on pituitary somatotrophs — while adding a fatty-acid-derived modification at the N-terminus to alter its pharmacological profile relative to the native, short-lived hormone.

The compound advanced through dose-ranging studies in the mid-2000s into two large multicenter Phase 3 trials in HIV-infected adults with abdominal fat accumulation. Pooled results from 806 patients supported its FDA approval in November 2010 under the trade name Egrifta, indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It remains the only GHRH analog to have reached FDA approval, which is why it anchors much of the published GHRH-analog literature that research laboratories reference today.

What Is the Chemical Structure of Tesamorelin?

Tesamorelin replicates the complete 44-amino-acid sequence of human GHRH(1–44) and carries a trans-3-hexenoyl group attached to the N-terminal tyrosine. This single modification is the defining structural feature that separates tesamorelin from both native GHRH and shorter GHRH fragments such as sermorelin.

• Amino acids: 44 (full-length GHRH analog)
• N-terminal modification: trans-3-hexenoyl group
• Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular weight: ~5,136 Da
• CAS number: 218949-48-5 (free base)
• Synonyms: TH9507, Egrifta (clinical trade name)

How Does Tesamorelin Act on the GH Axis in Research Models?

Tesamorelin's pharmacology follows the classical GHRH signaling cascade studied in endocrine literature:

• GHRH receptor binding — tesamorelin binds the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on anterior pituitary somatotrophs.
• Pulsatile GH release — receptor activation stimulates the release of endogenous growth hormone in its physiological pulsatile pattern, rather than supplying GH directly.
• IGF-1 elevation — circulating GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1), the principal downstream mediator. Published trials consistently report IGF-1 increases within the physiological range.
• Lipolytic signaling — GH-axis activation is associated in the literature with increased lipolysis and altered adipose-tissue metabolism, which is the mechanistic basis for the compound's investigation in fat-accumulation models.

A concept frequently discussed in the literature is that stimulating endogenous pulsatile GH release preserves the body's feedback regulation, in contrast to direct GH administration, which can suppress endogenous secretion. This distinction is part of why GHRH analogs became a distinct research focus from recombinant GH itself.

What Are Researchers Studying Tesamorelin For?

Researchers study tesamorelin primarily as a tool for probing the growth hormone (GH) axis and its downstream effects on body composition and metabolism. Because the compound signals the pituitary to release endogenous GH in its natural pulsatile pattern, published studies use it to examine how GH signaling relates to fat distribution, lipid metabolism, liver fat, lean tissue, and age-related change in the GH–IGF-1 axis. The areas below are the endpoints investigators have actually measured in controlled studies. They describe the published literature on the clinical compound — not effects of research-grade material, which NUPEPS PEPTIDES supplies for laboratory use only.

Visceral adipose tissue. The most extensively documented research area is visceral adipose tissue (VAT), the deep abdominal fat depot. In the Phase 3 program in HIV-associated lipodystrophy, investigators measured VAT by CT imaging as the primary endpoint and reported reductions in the tesamorelin groups alongside preservation of subcutaneous fat — the finding that supported the compound's single FDA-approved indication. This dataset remains the reference example in the literature of a GHRH analog altering fat distribution.

Lipid metabolism. The same trial program tracked blood lipids as secondary endpoints, and study reports describe improvements in triglyceride levels and in the total-to-HDL cholesterol ratio in the studied population. This is why tesamorelin also appears in research on cardiometabolic risk markers, beyond its primary fat-distribution endpoints.

Liver fat. A further research area is hepatic fat. In a randomized trial in people with HIV and non-alcoholic fatty liver disease, investigators measured hepatic fat fraction by imaging over 12 months and reported a relative reduction compared with placebo. Liver fat is therefore a distinct endpoint category in the tesamorelin literature, separate from abdominal fat.

Lean body mass and muscle. Investigators have also examined lean tissue. Trial reports describe changes in lean body mass accompanying the fat-distribution findings, and related analyses have measured muscle area and density on CT imaging. For GH-axis researchers, these endpoints connect GH signaling to the maintenance of lean tissue — an area of interest in aging and muscle-wasting research.

Cognition and the aging GH–IGF-1 axis. Tesamorelin is also studied in brain-aging research. A randomized trial in older adults, including participants with mild cognitive impairment, measured cognitive performance alongside IGF-1 levels, with the clearest reported signal in executive function. This line of work treats the GH–IGF-1 axis as a variable in cognition research; it does not establish a cognitive claim for the compound.

What Has Published Research Investigated?

HIV-associated lipodystrophy: the Phase 3 program

The largest body of tesamorelin literature comes from the Phase 3 program in HIV-infected adults with excess abdominal fat. In a 26-week randomized, double-blind trial of 412 patients, tesamorelin reduced visceral adipose tissue (VAT) measured by CT by 15.2%, compared with a 5.0% increase on placebo; triglycerides and the total-to-HDL cholesterol ratio improved, and IGF-1 rose 81% from baseline. No significant differences in glycemic measures were observed between groups.

A pooled analysis of the two Phase 3 trials (806 patients total) with a 52-week safety extension reported that VAT reductions were maintained through one year of continued treatment, that abdominal subcutaneous fat was preserved, and that lipid and body-image measures improved — again without clinically meaningful changes in glucose parameters.

Liver fat in HIV-associated NAFLD

A randomized, double-blind, multicenter trial investigated tesamorelin in 61 people with HIV and non-alcoholic fatty liver disease (NAFLD). After 12 months, hepatic fat fraction fell 37% in relative terms versus placebo, and 35% of tesamorelin-treated participants reached a hepatic fat fraction below 5%, compared with 4% on placebo. Glucose parameters did not differ between groups. The authors concluded tesamorelin might be beneficial in this population while noting that longer studies of liver histology were needed.

Cognition and the GH–IGF-1 axis

A 20-week randomized, double-blind, placebo-controlled trial in 152 adults (ages 55–87), including both healthy older adults and adults with mild cognitive impairment, examined a stabilized GHRH analog — tesamorelin — and cognitive performance. The authors reported a favorable effect on cognition overall, with the clearest signal in executive function, alongside a 117% increase in IGF-1 levels that remained within the physiological range and a 7.4% reduction in percent body fat. They called for longer-duration trials to examine the findings further.

What the literature does not establish

These are findings from controlled trials in specific study populations. They describe what researchers observed under trial conditions — not general claims about the compound, and not a basis for any use outside supervised clinical or laboratory settings. Research laboratories use tesamorelin as a defined tool compound for probing GH-axis biology, not as a therapeutic agent.

How Does Tesamorelin Compare to Sermorelin and CJC-1295 (No DAC)?

Tesamorelin, sermorelin, and CJC-1295 (no DAC) are the three GHRH-related peptides most commonly encountered in research contexts. They differ in length, structure, and research history:

• Length: Tesamorelin — 44 amino acids · Sermorelin — 29 amino acids · CJC-1295 (No DAC) — 29 amino acids
• Base structure: Tesamorelin — Full-length human GHRH(1–44) · Sermorelin — Human GHRH(1–29) fragment · CJC-1295 (No DAC) — Modified GRF(1–29)
• Key modification: Tesamorelin — N-terminal trans-3-hexenoyl group · Sermorelin — None (native fragment sequence) · CJC-1295 (No DAC) — Four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷); no drug-affinity complex
• Approx. molecular weight: Tesamorelin — ~5,136 Da · Sermorelin — ~3,358 Da · CJC-1295 (No DAC) — ~3,366 Da
• Most-studied research area: Tesamorelin — GH-axis signaling in adipose-tissue and metabolic models · Sermorelin — GH-axis physiology; historical GH-deficiency diagnostic research · CJC-1295 (No DAC) — GH-axis signaling in preclinical models
• Regulatory status: Tesamorelin — FDA-approved medicine (Egrifta, 2010); research material is RUO · Sermorelin — Formerly marketed; research material is RUO · CJC-1295 (No DAC) — Not FDA approved; research use only

The practical distinction for laboratories: tesamorelin is the full-length analog with the largest published trial record; sermorelin is the shorter native fragment with an older research history; CJC-1295 (no DAC) is a synthetically modified fragment studied in preclinical GH-axis work. Our overview of tesamorelin's role in fat-metabolism research goes deeper into the adipose-tissue literature.

Is Tesamorelin Approved for Human Use?

Yes — with important qualifications. Tesamorelin was approved by the FDA in 2010 as the prescription medicine Egrifta, indicated specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is prescription-only, and its approved labeling does not extend to weight-loss management or any other indication.

For research laboratories, the relevant facts are:

• Clinical status: FDA-approved prescription medicine for one specific indication (HIV-associated lipodystrophy).
• Research status: Research-grade tesamorelin is supplied strictly as a reference material for laboratory and in vitro research. It is not for human or veterinary use, and NUPEPS PEPTIDES products are never intended for the diagnosis, treatment, cure, or prevention of any disease.
• Evidence boundary: The strongest published data come from trials in adults with HIV; findings from that population should not be generalized to other contexts.

What Does the Published Research Show? Key Studies

Selected peer-reviewed studies frequently cited in tesamorelin literature:

• Falutz et al. (2007) — Phase 3 randomized trial (412 patients, 26 weeks) of tesamorelin in HIV-associated abdominal fat accumulation; reported VAT reduction and lipid improvements. New England Journal of Medicine.
• Falutz et al. (2010) — pooled analysis of the two Phase 3 trials (806 patients) with 52-week extension data; VAT reduction maintained at one year. Journal of Clinical Endocrinology & Metabolism.
• Stanley et al. (2019) — randomized, double-blind, multicenter trial of tesamorelin in HIV-associated NAFLD (61 patients, 12 months); reported hepatic fat fraction reduction. The Lancet HIV.
• Baker et al. (2012) — randomized, double-blind, placebo-controlled trial of a stabilized GHRH analog (tesamorelin) and cognitive function in 152 older adults over 20 weeks. Archives of Neurology.

How Is Tesamorelin Handled in the Laboratory?

Like most research peptides, tesamorelin ships as a lyophilized powder and requires disciplined handling:

• Verify identity and purity against the batch-specific COA before use — our guide on how to read a peptide COA walks through the HPLC and mass-spec sections.
• Reconstitute with sterile technique using an appropriate diluent chosen per the lab's own validated protocol; see our step-by-step reconstitution guide.
• Store correctly — lyophilized at −20 °C, protected from light and moisture; reconstituted aliquots refrigerated short term or frozen single-use. Details in our peptide storage guide.

Tesamorelin at NUPEPS PEPTIDES

NUPEPS PEPTIDES supplies research-grade tesamorelin as Tesamorelin 10 mg. Every batch is tested for purity, quantity, and sterility, with batch-specific COAs verifying 99%+ purity.

Browse the full catalog of research peptides or see how NUPEPS PEPTIDES tests every batch.

Frequently Asked Questions

What does tesamorelin stand for?

Tesamorelin is not an acronym. It was developed under the code name TH9507 (Theratechnologies) and is marketed clinically as Egrifta.

How many amino acids does tesamorelin have?

Forty-four. It is a full-length analog of human GHRH(1–44) with an N-terminal trans-3-hexenoyl modification, giving it a molecular weight of about 5,136 daltons.

Is tesamorelin FDA approved?

Yes — as the prescription medicine Egrifta, approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Research-grade tesamorelin is a separate supply category, strictly for laboratory research use only.

What is the difference between tesamorelin and sermorelin?

Tesamorelin is a 44-amino-acid full-length GHRH analog with an N-terminal hexenoyl modification; sermorelin is the shorter 29-amino-acid GHRH(1–29) fragment with no modifications. Tesamorelin has the larger modern published trial record.

What is the difference between tesamorelin and CJC-1295?

Tesamorelin replicates full-length human GHRH with one N-terminal modification; CJC-1295 (no DAC) is a 29-amino-acid fragment carrying four synthetic amino-acid substitutions and no drug-affinity complex. They are distinct molecules studied in overlapping GH-axis research.

How should tesamorelin be stored in the lab?

Lyophilized vials: freezer (−20 °C), protected from light and moisture. After reconstitution: refrigerate short term or freeze single-use aliquots; avoid repeated freeze–thaw cycles. See our peptide storage guide.

(article-specific, append to the existing FAQ block)

What benefits of tesamorelin have been studied?

In the published literature, "benefits" refers to endpoints measured in controlled studies: visceral adipose tissue reduction, improvements in triglyceride and cholesterol-ratio measures, and reduced hepatic fat fraction, reported mainly in adults with HIV under clinical supervision. Findings in those populations do not generalize to other contexts, and research-grade tesamorelin is sold strictly for laboratory research use only.

Has tesamorelin been studied for belly fat?

Yes — visceral abdominal fat is its most-studied endpoint. Phase 3 trials in HIV-associated lipodystrophy measured visceral adipose tissue by CT imaging, and the results supported FDA approval of the prescription medicine Egrifta for that specific indication in 2010. The approved indication covers that patient population only.

Is tesamorelin studied for liver fat?

Yes. A randomized, double-blind trial in people with HIV and non-alcoholic fatty liver disease measured hepatic fat fraction by imaging over 12 months and reported a relative reduction versus placebo. The authors noted that longer studies of liver tissue outcomes were still needed.

Does tesamorelin raise IGF-1 in studies?

Published trials consistently report that tesamorelin increases circulating IGF-1, the downstream mediator of growth hormone, with reported levels remaining within the physiological range. Researchers treat IGF-1 as a standard biomarker confirming GH-axis engagement in tesamorelin study designs.

Key Takeaways

Tesamorelin occupies a unique position among research peptides: a full-length GHRH analog with a genuine Phase 3 trial record, an FDA approval in a specific clinical niche, and a defined mechanism — GHRH-receptor-driven pulsatile GH release — that makes it a precise tool for studying GH-axis biology. For laboratories, the fundamentals are the same as with any peptide reference material: verified identity, documented purity, and disciplined handling from vial to assay.

Common questions about ordering and shipping are answered in our FAQs.

Research Use Only disclaimer: All NUPEPS PEPTIDES products, including tesamorelin, are sold strictly for laboratory and in vitro research use only. They are not intended for human or veterinary use, nor for the diagnosis, treatment, cure, or prevention of any disease. This article is for informational purposes only and summarizes published scientific literature; it does not constitute medical or scientific advice.

Further Reading

• The Application of Tesamorelin in Fat Metabolism in HIV Patients
• What Is a Peptide COA and Why Does It Matter for Research?